Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Protein C Deficiency

  • Author: Adam Cuker, MD, MS; Chief Editor: Perumal Thiagarajan, MD  more...
 
Updated: Jan 21, 2016
 

Background

Protein C deficiency is a congenital or acquired condition that leads to increased risk for thrombosis. Congenital protein C deficiency is one of several inherited thrombophilias, which are a heterogeneous group of genetic disorders associated with an elevated risk of venous thromboembolism. Other inherited thrombophilias include the factor V Leiden mutation, the prothrombin gene mutation, dysfibrinogenemia, protein S deficiency, and antithrombin deficiency.

This article will focus on the pathophysiology, prevalence, clinical manifestations, diagnosis, and treatment of hereditary protein C deficiency. Causes of acquired protein C deficiency are also addressed (see Causes).

For patient education information, see the Deep Vein Thrombosis Health Center, as well as Pulmonary Embolism.

Next

Pathophysiology

The protein C pathway

Protein C is a 62-kD, vitamin K-dependent glycoprotein synthesized in the liver. It circulates in the blood as an inactive zymogen at a concentration of 4 μg/mL. Its activation into the serine-protease-like enzyme, activated protein C (aPC), is catalyzed by thrombin when it is bound to the endothelial proteoglycan thrombomodulin.[1, 2] The protein C pathway is illustrated in the image below.

The protein C pathway. APC = activated protein C; The protein C pathway. APC = activated protein C; PC = protein C; S= protein S; T = thrombin; TM = thrombomodulin; Va = factor Va; VIII = factor VIIIa.

Activated protein C (aPC) exerts its anticoagulant activity primarily through inactivation of coagulation factors Va and VIIIa, which are required for factor X activation and thrombin generation. The catalytic activity of activated protein C (aPC) is greatly enhanced by the vitamin K-dependent cofactor protein S.[3]

Aside from its role in coagulation, aPC subserves anti-inflammatory and cytoprotective functions, which are mediated through the endothelial protein C receptor and the protease-activated receptor-1 (PAR-1).[4, 5]

A deficiency of activated protein C (aPC) disturbs the delicate balance between procoagulant and anticoagulant proteins and engenders a prothrombotic environment. The role of activated protein C (aPC) and other anticoagulant proteins in this balance appears to be especially important in the slow-flowing venous circulation, in which there is prolonged exposure of procoagulant proteins and platelet phospholipids to the vessel wall. This may explain, in part, why protein C deficiency appears to be associated primarily with venous thrombosis.

Genetics of protein C deficiency

Heterozygous protein C deficiency is inherited in an autosomal dominant fashion. The gene for protein C is located on the long arm of chromosome 2 and nearly 200 pathogenic mutations of this gene have been described.[6, 7] These mutations are divided into 2 types — type I and type II — on the basis of whether they cause a quantitative (type I) or functional (type II) deficiency of protein C.

Type I deficiency

Type I protein C deficiency refers to a quantitative deficiency in the plasma protein C concentration. Heterozygous individuals typically demonstrate protein C antigen and activity levels that are approximately one half that of normal patient plasma. A range of causative genetic alterations within the protein C promoter region and splice sites as well as in the coding sequence of the protein C gene itself have been reported.[6]

There is marked phenotypic variation among families with heterozygous type I protein C deficiency. Some families exhibit a severe thrombotic tendency, whereas others remain asymptomatic.[8, 9, 10] Interestingly, this variability is seen even among different pedigrees that harbor the same protein C mutation, suggesting that the mutation itself does not fully explain the phenotypic variability.[11] The presence of a second thrombophilic mutation such as factor V Leiden has been associated with a more severe phenotype in some protein C-deficient kindreds.[12]

Type II deficiency

Type II protein C deficiency is less common than type I disease, and is associated with decreased functional activity and normal immunologic levels of protein C. A number of point mutations within the protein C gene giving rise to this disorder have been described.[6]

Previous
Next

Epidemiology

Frequency

United States

The frequency of protein C deficiency in the United States is similar to that found internationally.

International

Protein C deficiency by plasma level alone is found in 1 in 200 to 1 in 500 persons in the general population.[13, 14] However, many affected individuals remain asymptomatic throughout life. Protein C deficiency is present in approximately 2-5% of patients presenting with VTE.[15, 16, 17] Severe homozygous or compound heterozygous protein C deficiency occurs in approximately 1 in 500,000 to 1 in 750,000 live births.

Mortality/Morbidity

Clinical manifestations of heterozygous protein C deficiency include VTE and warfarin-induced skin necrosis (WISN). Whether the risk of pregnancy loss is increased in this disorder is controversial. Heterozygous protein C deficiency does not appear to be associated with an elevated risk of arterial thrombosis.

Homozygous and compound heterozygous protein C deficiency are classically associated with neonatal purpura fulminans (NPF); intracranial thromboembolism may also occur in neonates.[18]     Occasionally, patients present with VTE in childhood or adolescence.

Venous thromboembolism

The cardinal clinical manifestation of heterozygous protein C deficiency is VTE. The risk of VTE in this population is roughly seven-fold over that of the general population.[19, 20] Approximately 40% of patients with VTE have one of the usual thrombotic risk factors, such as pregnancy, the postpartum state, hormonal therapy, surgery, or immobilization.[21] The remaining 60% present with unprovoked VTE.

The most common sites of thrombosis are the deep veins of the lower extremities, although an elevated risk of mesenteric vein and cerebral sinus thrombosis is also well-documented.[22, 23, 24] Approximately 40% of patients with protein C deficiency present with evidence of pulmonary embolism, and roughly 60% suffer recurrent thrombosis if anticoagulation is discontinued.[21] The risk of VTE increases with age and, among heterozygotes, thrombosis is unusual before age 20 years. Rare homozygotes and compound heterozygotes who do not manifest NPF in infancy may present with VTE later in childhood or adolescence.[25]

Warfarin-induced skin necrosis

WISN is a potentially catastrophic complication of warfarin therapy that arises as a consequence of the different half-lives of the vitamin K-dependent proteins. One day after initiation of usual doses of warfarin, protein C activity is reduced by approximately 50%. Owing to their longer half-lives, the levels of the vitamin K-dependent clotting factors II, IX, and X decline more slowly (factor VII activity declines at approximately the same rate as protein C). The reduced level of protein C activity relative to these other procoagulant molecules creates a transient hypercoagulable state. This effect is more pronounced when large loading doses of warfarin are administered. Indeed, WISN typically occurs during the first few days of warfarin therapy, often when daily doses in excess of 10 mg are administered.[26, 27]

The skin lesions of WISN arise on the extremities, torso, breasts, and penis. They begin as erythematous macules and, if appropriate therapy is not initiated promptly, evolve to become purpuric and necrotic (see image below). Dermal biopsy demonstrates ischemic necrosis of the cutaneous tissue with cutaneous vessel thrombosis and surrounding interstitial hemorrhage.[28]

A patient with warfarin-induced skin necrosis. A patient with warfarin-induced skin necrosis.

Although protein C deficiency is a strong risk factor for the development of WISN, approximately two thirds of patients with WISN do not have underlying hereditary protein C deficiency.[29] Other conditions reported in association with WISN include acquired protein C deficiency (see Causes)[30] and heterozygous protein S deficiency.[31]

See Deterrence/Prevention for the discussion of prevention and treatment of WISN.

Pregnancy loss

Protein C deficiency may be weakly associated with late and recurrent pregnancy loss. In the European Prospective Cohort on Thrombophilia, the odds ratio (OR) for stillbirth (defined as pregnancy loss at >28 weeks' gestation) among women with an inherited thrombophilia was 3.6 (95% confidence interval [CI] 1.4-9.4), whereas the risk of miscarriage before 28 weeks' gestation in this cohort was not significantly different than that of nonthrombophilic women.[32] Among the subgroup of thrombophilia subjects with congenital protein C deficiency, the OR of stillbirth was 2.3 (95% CI 0.6-8.3).[33, 32] In a meta-analysis of 633 subjects with hereditary protein C deficiency, the association with recurrent fetal loss was likewise nonsignificant (OR 1.57; 95% CI 0.23-10.54).[34]

Arterial thrombosis

There are several case reports of arterial stroke[35, 36] and myocardial infarction[37] occurring in young adults with congenital protein C deficiency. However, the results of larger studies are conflicting[38, 39, 40, 41, 42] and the existence of an association between protein C deficiency and arterial thrombosis remains controversial.

Peripheral arterial disease

In a study of 106 patients with peripheral arterial disease (PAD) and 44 with abdominal aortic aneurysm (AAA), Komai and colleagues found that the incidences of protein C deficiency was 4.7% in patients with PAD and 4.% in patients with AAA — higher rates than those observed in the general population. Protein C activity levels were significantly lower in PAD patients with critical limb ischemia than in those with intermittent claudication. In multivariate logistic regression analysis, lower protein C activity and female gender were determinant factors of critical limb ischemia.[43]

Neonatal purpura fulminans

NPF is a life-threatening condition that occurs in newborns with homozygous or compound heterozygous protein C deficiency, usually during the first several days of life. Affected neonates present with diffuse ecchymoses (see image below). Skin biopsy demonstrates extensive thrombosis of cutaneous venous and arterial channels, much as is observed in WISN.[44, 45] Laboratory testing reveals severe deficiency (< 1% of normal) of immunologic protein C levels.[46] Expeditious treatment with an exogenous source of protein C, discussed below in Treatment, Medical Care, is paramount.

{Imagenum3:1518494

Race

Congenital protein C deficiency is recognized as a cause of thrombophilia around the world. Studies in blacks and Asians suggest that its prevalence in these populations is on par with its frequency of occurrence in whites.[47, 48] In contrast, the factor V Leiden and prothrombin gene mutations (see Hypercoagulability: Hereditary Thrombophilia and Lupus Anticoagulants Associated With Venous Thrombosis and Emboli) occur with substantially greater frequency in white than in nonwhite populations.

Sex

As would be expected for an autosomal genetic disorder, the prevalence of hereditary protein C deficiency is similar in men and women. However, pregnancy, the postpartum state, and estrogen-containing hormonal therapy are important risk factors for the development of VTE that are unique to women.

Age

Preterm infants have protein C levels approximately 10-15% of normal adult levels; neonates, approximately 35%; and adolescents, 80%. Protein C levels increase approximately 4% per decade in adulthood[49, 50] ; nonetheless, the risk of thrombosis in individuals with heterozygous protein C deficiency increases with age. The median age at onset of VTE in heterozygous individuals is 30-40 years, and thrombosis is rare before age 20 years.[51]

In contrast, homozygous or compound heterozygous protein C deficiency classically manifests as NPF in the first several hours to days of life. Rare patients with homozygous or compound heterozygous deficiency may present with VTE during childhood or adolescence.[25]

Previous
 
 
Contributor Information and Disclosures
Author

Adam Cuker, MD, MS Assistant Professor of Medicine, Assistant Professor of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine

Adam Cuker, MD, MS is a member of the following medical societies: American College of Physicians, American Society of Hematology, Anticoagulation Forum, Hemostasis and Thrombosis Research Society, International Society on Thrombosis and Haemostasis

Disclosure: Received consulting fee from Genzyme for consulting; Received consulting fee from Amgen for consulting; Received grant/research funds from T2 Biosystems for other; Received grant/research funds from Spark Therapeutics for other. .

Coauthor(s)

Eleanor S Pollak, MD Associate Director of Special Coagulation, Associate Professor, Department of Pathology and Laboratory Medicine, Section of Hematology and Coagulation, University of Pennsylvania

Eleanor S Pollak, MD is a member of the following medical societies: American Society of Hematology, College of American Pathologists, National Multiple Sclerosis Society

Disclosure: Nothing to disclose.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Chief Editor

Perumal Thiagarajan, MD Professor, Department of Pathology and Medicine, Baylor College of Medicine; Director, Transfusion Medicine and Hematology Laboratory, Michael E DeBakey Veterans Affairs Medical Center

Perumal Thiagarajan, MD is a member of the following medical societies: American College of Physicians, American Society for Clinical Investigation, Association of American Physicians, American Society for Biochemistry and Molecular Biology, American Heart Association, American Society of Hematology, Royal College of Physicians

Disclosure: Nothing to disclose.

Additional Contributors

David Aboulafia, MD Medical Director, Bailey-Boushay House, Clinical Professor, Department of Medicine, Division of Hematology, Attending Physician, Section of Hematology/Oncology, Virginia Mason Clinic; Investigator, Virginia Mason Community Clinic Oncology Program/SWOG

David Aboulafia, MD is a member of the following medical societies: American College of Physicians, American Medical Association, AMDA - The Society for Post-Acute and Long-Term Care Medicine, American Society of Hematology, Infectious Diseases Society of America, Phi Beta Kappa

Disclosure: Nothing to disclose.

References
  1. Dahlback B. Advances in understanding pathogenic mechanisms of thrombophilic disorders. Blood. 2008 Jul 1. 112(1):19-27. [Medline]. [Full Text].

  2. Clouse LH, Comp PC. The regulation of hemostasis: the protein C system. N Engl J Med. 1986 May 15. 314(20):1298-304. [Medline].

  3. Walker FJ. Regulation of activated protein C by a new protein. A possible function for bovine protein S. J Biol Chem. 1980 Jun 25. 255(12):5521-4. [Medline]. [Full Text].

  4. Mosnier LO, Zlokovic BV, Griffin JH. The cytoprotective protein C pathway. Blood. 2007 Apr 15. 109(8):3161-72. [Medline]. [Full Text].

  5. Danese S, Vetrano S, Zhang L, Poplis VA, Castellino FJ. The protein C pathway in tissue inflammation and injury: pathogenic role and therapeutic implications. Blood. 2010 Feb 11. 115(6):1121-30. [Medline]. [Full Text].

  6. Reitsma PH, Bernardi F, Doig RG, Gandrille S, on behalf of the Subcommittee on Plasma Coagulation Inhibitors of the Scientific and Standardization Committee of the ISTH. Protein C deficiency: a database of mutations, 1995 update. Thromb Haemost. 1995 May. 73(5):876-89. [Medline].

  7. D'Ursi P, Marino F, Caprera A, Milanesi L, Faioni EM, Rovida E. ProCMD: a database and 3D web resource for protein C mutants. BMC Bioinformatics. 2007 Mar 8. 8 Suppl 1:S11. [Medline]. [Full Text].

  8. Bovill EG, Bauer KA, Dickerman JD, Callas P, West B. The clinical spectrum of heterozygous protein C deficiency in a large New England kindred. Blood. 1989 Feb 15. 73(3):712-7. [Medline]. [Full Text].

  9. Broekmans AW, Veltkamp JJ, Bertina RM. Congenital protein C deficiency and venous thromboembolism. A study of three Dutch families. N Engl J Med. 1983 Aug 11. 309(6):340-4. [Medline].

  10. Horellou MH, Conard J, Bertina RM, Samama M. Congenital protein C deficiency and thrombotic disease in nine French families. Br Med J (Clin Res Ed). 1984 Nov 10. 289(6454):1285-7. [Medline]. [Full Text].

  11. Reitsma PH, Poort SR, Allaart CF, Briet E, Bertina RM. The spectrum of genetic defects in a panel of 40 Dutch families with symptomatic protein C deficiency type I: heterogeneity and founder effects. Blood. 1991 Aug 15. 78(4):890-4. [Medline]. [Full Text].

  12. Mustafa S, Mannhalter C, Rintelen C,et al. Clinical features of thrombophilia in families with gene defects in protein C or protein S combined with factor V Leiden. Blood Coagul Fibrinolysis. 1998 Jan. 9(1):85-9. [Medline].

  13. Tait RC, Walker ID, Reitsma PH, et al. Prevalence of protein C deficiency in the healthy population. Thromb Haemost. 1995 Jan. 73(1):87-93. [Medline].

  14. Miletich J, Sherman L, Broze G Jr. Absence of thrombosis in subjects with heterozygous protein C deficiency. N Engl J Med. 1987 Oct 15. 317(16):991-6. [Medline].

  15. Mateo J, Oliver A, Borrell M, Sala N, Fontcuberta J. Laboratory evaluation and clinical characteristics of 2,132 consecutive unselected patients with venous thromboembolism--results of the Spanish Multicentric Study on Thrombophilia (EMET-Study). Thromb Haemost. 1997 Mar. 77(3):444-51. [Medline].

  16. Gladson CL, Scharrer I, Hach V, Beck KH, Griffin JH. The frequency of type I heterozygous protein S and protein C deficiency in 141 unrelated young patients with venous thrombosis. Thromb Haemost. 1988 Feb 25. 59(1):18-22. [Medline].

  17. Heijboer H, Brandjes DP, Buller HR, Sturk A, ten Cate JW. Deficiencies of coagulation-inhibiting and fibrinolytic proteins in outpatients with deep-vein thrombosis. N Engl J Med. 1990 Nov 29. 323(22):1512-6. [Medline].

  18. Ichiyama M, Ohga S, Ochiai M, Fukushima K, Ishimura M, Torio M, et al. Fetal hydrocephalus and neonatal stroke as the first presentation of protein C deficiency. Brain Dev. 2016 Feb. 38 (2):253-6. [Medline].

  19. Martinelli I, Mannucci PM, De Stefano V, et al. Different risks of thrombosis in four coagulation defects associated with inherited thrombophilia: a study of 150 families. Blood. 1998 Oct 1. 92(7):2353-8. [Medline]. [Full Text].

  20. Koster T, Rosendaal FR, Briet E, et al. Protein C deficiency in a controlled series of unselected outpatients: an infrequent but clear risk factor for venous thrombosis (Leiden Thrombophilia Study). Blood. 1995 May 15. 85(10):2756-61. [Medline]. [Full Text].

  21. Pabinger I, Schneider B, for the Gesellschaft fur Thrombose- und Hamostaseforschung (GTH) Study Group on Natural Inhibitors. Thrombotic risk in hereditary antithrombin III, protein C, or protein S deficiency. A cooperative, retrospective study. Arterioscler Thromb Vasc Biol. 1996 Jun. 16(6):742-8. [Medline]. [Full Text].

  22. de Bruijn SF, Stam J, Koopman MM, Vandenbroucke JP, for the Cerebral Venous Sinus Thrombosis Study Group. Case-control study of risk of cerebral sinus thrombosis in oral contraceptive users and in [correction of who are] carriers of hereditary prothrombotic conditions. BMJ. 1998 Feb 21. 316(7131):589-92. [Medline]. [Full Text].

  23. Momoi A, Komura Y, Kumon I, et al. Mesenteric venous thrombosis in hereditary protein C deficiency with the mutation at Arg169 (CGG-TGG). Intern Med. 2003 Jan. 42(1):110-6. [Medline]. [Full Text].

  24. Wysokinska EM, Wysokinski WE, Brown RD, et al. Thrombophilia differences in cerebral venous sinus and lower extremity deep venous thrombosis. Neurology. 2008 Feb 19. 70(8):627-33. [Medline].

  25. Melissari E, Kakkar VV. Congenital severe protein C deficiency in adults. Br J Haematol. 1989 Jun. 72(2):222-8. [Medline].

  26. McGehee WG, Klotz TA, Epstein DJ, Rapaport SI. Coumarin necrosis associated with hereditary protein C deficiency. Ann Intern Med. 1984 Jul. 101(1):59-60. [Medline].

  27. Bauer KA. Coumarin-induced skin necrosis. Arch Dermatol. 1993 Jun. 129(6):766-8. [Medline].

  28. Faraci PA, Deterling RA Jr, Stein AM, Rheinlander HF, Cleveland RJ. Warfarin induced necrosis of the skin. Surg Gynecol Obstet. 1978 May. 146(5):695-700. [Medline].

  29. Broekmans AW, Teepe RG, van der Meer FJ, Briet E, Bertina RM. Protein C (PC) and coumarin-induced skin necrosis. Thromb Res. 1986. 41(suppl 1):137.

  30. Teepe RG, Broekmans AW, Vermeer BJ, Nienhuis AM, Loeliger EA. Recurrent coumarin-induced skin necrosis in a patient with an acquired functional protein C deficiency. Arch Dermatol. 1986 Dec. 122(12):1408-12. [Medline].

  31. Sallah S, Abdallah JM, Gagnon GA. Recurrent warfarin-induced skin necrosis in kindreds with protein S deficiency. Haemostasis. 1998 Jan-Feb. 28(1):25-30. [Medline].

  32. Preston FE, Rosendaal FR, Walker ID, et al. Increased fetal loss in women with heritable thrombophilia. Lancet. 1996 Oct 5. 348(9032):913-6. [Medline].

  33. Vossen CY, Preston FE, Conard J, et al. Hereditary thrombophilia and fetal loss: a prospective follow-up study. J Thromb Haemost. 2004 Apr. 2(4):592-6. [Medline]. [Full Text].

  34. Rey E, Kahn SR, David M, Shrier I. Thrombophilic disorders and fetal loss: a meta-analysis. Lancet. 2003 Mar 15. 361(9361):901-8. [Medline].

  35. Kohler J, Kasper J, Witt I, von Reutern GM. Ischemic stroke due to protein C deficiency. Stroke. 1990 Jul. 21(7):1077-80. [Medline]. [Full Text].

  36. Camerlingo M, Finazzi G, Casto L, et al. Inherited protein C deficiency and nonhemorrhagic arterial stroke in young adults. Neurology. 1991 Sep. 41(9):1371-3. [Medline].

  37. Peterman MA, Roberts WC. Syndrome of protein C deficiency and anterior wall acute myocardial infarction at a young age from a single coronary occlusion with otherwise normal coronary arteries. Am J Cardiol. 2003 Sep 15. 92(6):768-70. [Medline].

  38. Douay X, Lucas C, Caron C, Goudemand J, Leys D. Antithrombin, protein C and protein S levels in 127 consecutive young adults with ischemic stroke. Acta Neurol Scand. 1998 Aug. 98(2):124-7. [Medline].

  39. Munts AG, van Genderen PJ, Dippel DW, van Kooten F, Koudstaal PJ. Coagulation disorders in young adults with acute cerebral ischaemia. J Neurol. 1998 Jan. 245(1):21-5. [Medline].

  40. Boekholdt SM, Kramer MH. Arterial thrombosis and the role of thrombophilia. Semin Thromb Hemost. 2007 Sep. 33(6):588-96. [Medline].

  41. Folsom AR, Ohira T, Yamagishi K, Cushman M. Low protein C and incidence of ischemic stroke and coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study. J Thromb Haemost. 2009 Nov. 7(11):1774-8. [Medline]. [Full Text].

  42. Kenet G, Lütkhoff LK, Albisetti M, Bernard T, Bonduel M, Brandao L, et al. Impact of thrombophilia on risk of arterial ischemic stroke or cerebral sinovenous thrombosis in neonates and children: a systematic review and meta-analysis of observational studies. Circulation. 2010 Apr 27. 121(16):1838-47. [Medline].

  43. Komai H, Shindo S, Sato M, Ogino H. Reduced Protein C Activity Might be Associated With Progression of Peripheral Arterial Disease. Angiology. 2014 Aug 12. [Medline].

  44. Seligsohn U, Berger A, Abend M, et al. Homozygous protein C deficiency manifested by massive venous thrombosis in the newborn. N Engl J Med. 1984 Mar 1. 310(9):559-62. [Medline].

  45. Peters C, Casella JF, Marlar RA, Montgomery RR, Zinkham WH. Homozygous protein C deficiency: observations on the nature of the molecular abnormality and the effectiveness of warfarin therapy. Pediatrics. 1988 Feb. 81(2):272-6. [Medline].

  46. Marciniak E, Wilson HD, Marlar RA. Neonatal purpura fulminans: a genetic disorder related to the absence of protein C in blood. Blood. 1985 Jan. 65(1):15-20. [Medline]. [Full Text].

  47. Patel RK, Ford E, Thumpston J, Arya R. Risk factors for venous thrombosis in the black population. Thromb Haemost. 2003 Nov. 90(5):835-8. [Medline].

  48. Sakata T, Kario K, Katayama Y, et al. Studies on congenital protein C deficiency in Japanese: prevalence, genetic analysis, and relevance to the onset of arterial occlusive diseases. Semin Thromb Hemost. 2000. 26(1):11-6. [Medline].

  49. Nardi M, Karpatkin M. Prothrombin and protein C in early childhood: normal adult levels are not achieved until the fourth year of life. J Pediatr. 1986 Nov. 109(5):843-5. [Medline].

  50. van Teunenbroek A, Peters M, Sturk A, Borm JJ, Breederveld C. Protein C activity and antigen levels in childhood. Eur J Pediatr. 1990 Aug. 149(11):774-8. [Medline].

  51. Lensen RP, Rosendaal FR, Koster T, et al. Apparent different thrombotic tendency in patients with factor V Leiden and protein C deficiency due to selection of patients. Blood. 1996 Dec 1. 88(11):4205-8. [Medline]. [Full Text].

  52. Mitchell CA, Rowell JA, Hau L, Young JP, Salem HH. A fatal thrombotic disorder associated with an acquired inhibitor of protein C. N Engl J Med. 1987 Dec 24. 317(26):1638-42. [Medline].

  53. Gordon B, Haire W, Ruby E, et al. Prolonged deficiency of protein C following hematopoietic stem cell transplantation. Bone Marrow Transplant. 1996 Mar. 17(3):415-9. [Medline].

  54. Gerson WT, Dickerman JD, Bovill EG, Golden E. Severe acquired protein C deficiency in purpura fulminans associated with disseminated intravascular coagulation: treatment with protein C concentrate. Pediatrics. 1993 Feb. 91(2):418-22. [Medline].

  55. Yilmaz S, Gunaydin S. Inherited risk factors in low-risk venous thromboembolism in patients under 45 years. Interact Cardiovasc Thorac Surg. 2014 Oct 17. [Medline].

  56. Michiels JJ, Hamulyak K. Laboratory diagnosis of hereditary thrombophilia. Semin Thromb Hemost. 1998. 24(4):309-20. [Medline].

  57. Dolan G, Neal K, Cooper P, Brown P, Preston FE. Protein C, antithrombin III and plasminogen: effect of age, sex and blood group. Br J Haematol. 1994 Apr. 86(4):798-803. [Medline].

  58. Martinoli JL, Stocker K. Fast functional protein C assay using Protac, a novel protein C activator. Thromb Res. 1986 Aug 1. 43(3):253-64. [Medline].

  59. Jones DW, Mackie IJ, Winter M, Gallimore M, Machin SJ. Detection of protein C deficiency during oral anticoagulant therapy--use of the protein C:factor VII ratio. Blood Coagul Fibrinolysis. 1991 Jun. 2(3):407-11. [Medline].

  60. Linn YC, Tien SL. Detection of protein C or protein S deficiency in patients on warfarin therapy--a study of nine patients. Ann Acad Med Singapore. 1994 Sep. 23(5):775-80. [Medline].

  61. Schramm W, Spannagl M, Bauer KA, et al. Treatment of coumarin-induced skin necrosis with a monoclonal antibody purified protein C concentrate. Arch Dermatol. 1993 Jun. 129(6):753-6. [Medline].

  62. Dreyfus M, Magny JF, Bridey F, et al. Treatment of homozygous protein C deficiency and neonatal purpura fulminans with a purified protein C concentrate. N Engl J Med. 1991 Nov 28. 325(22):1565-8. [Medline].

  63. Conard J, Bauer KA, Gruber A, et al. Normalization of markers of coagulation activation with a purified protein C concentrate in adults with homozygous protein C deficiency. Blood. 1993 Aug 15. 82(4):1159-64. [Medline]. [Full Text].

  64. Dreyfus M, Ladouzi A, Chambost H, et al, for the PROTEXEL Study Group. Treatment of inherited protein C deficiency by replacement therapy with the French purified plasma-derived protein C concentrate (PROTEXEL). Vox Sang. 2007 Oct. 93(3):233-40. [Medline].

  65. Hartman KR, Manco-Johnson M, Rawlings JS, Bower DJ, Marlar RA. Homozygous protein C deficiency: early treatment with warfarin. Am J Pediatr Hematol Oncol. 1989 Winter. 11(4):395-401. [Medline].

  66. Minford AM, Parapia LA, Stainforth C, Lee D. Treatment of homozygous protein C deficiency with subcutaneous protein C concentrate. Br J Haematol. 1996 Apr. 93(1):215-6. [Medline].

  67. Lee MJ, Kim KM, Kim JS, Kim YJ, Lee YJ, Ghim TT. Long-term survival of a child with homozygous protein C deficiency successfully treated with living donor liver transplantation. Pediatr Transplant. 2009 Mar. 13 (2):251-4. [Medline].

  68. Crowther MA, Ageno W, Garcia D, et al. Oral vitamin K versus placebo to correct excessive anticoagulation in patients receiving warfarin: a randomized trial. Ann Intern Med. 2009 Mar 3. 150(5):293-300. [Medline].

  69. Klein TE, Altman RB, Eriksson N, et al, for the International Warfarin Pharmacogenetics Consortium. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med. 2009 Feb 19. 360(8):753-64. [Medline]. [Full Text].

 
Previous
Next
 
The protein C pathway. APC = activated protein C; PC = protein C; S= protein S; T = thrombin; TM = thrombomodulin; Va = factor Va; VIII = factor VIIIa.
A patient with warfarin-induced skin necrosis.
A patient with neonatal purpura fulminans.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.